

Integrative Biochemical Diagnostics: From Prenatal Genomics to Environmental and Behavioral Biomarkers

Ian Pranandi

Department of Biochemistry, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia

Published Date: November 29, 2025

Article DOI: 10.65150/EP-jnsrr/V1E5/2025-05

ABSTRACT: Biochemical diagnostics are undergoing a profound transformation driven by advances in genomics, bioinformatics, environmental biosensing, and circadian physiology. This short review synthesizes emerging developments across these domains to propose an integrative framework for modern diagnostic practice. Non-invasive prenatal testing using cell-free fetal DNA and RNA has expanded early detection of genetic and developmental abnormalities, while bioinformatics-driven identification of salivary and metabolic biomarkers has enabled accessible, low-burden assessment of detoxification pathways and metabolic phenotypes. Environmental exposures such as microplastics and endocrine-disrupting chemicals add a critical external dimension to biochemical variation, interacting with culturally mediated behaviors and dietary patterns to shape population-level metabolic traits. Circadian rhythms introduce a temporal layer of physiological regulation, with artificial intelligence now capable of modeling hormonal and metabolic oscillations to improve diagnostic accuracy and chronotherapy planning. Together, these interconnected domains highlight the need for comprehensive, multidimensional diagnostic strategies that reflect the complexity of human biology. Integrating genetic, environmental, cultural, and temporal determinants offers a more precise and equitable pathway toward personalized medicine and population health monitoring.

KEYWORDS: Biochemical diagnostics, prenatal genomics, salivary biomarkers, environmental biosensing, circadian physiology, bioinformatics, microRNAs, artificial intelligence

1. INTRODUCTION

Biochemical diagnostics have undergone a profound transformation over the past two decades, evolving from traditional organ-based assessments toward molecular, non-invasive, and highly integrative approaches.¹ Early diagnostic strategies relied heavily on clinical symptoms, imaging, and invasive sampling, which, although effective, often provided only late or limited insight into underlying physiological and pathological processes.² Advances in molecular biology, bioinformatics, and high-throughput technologies have fundamentally reshaped this landscape by enabling clinicians and researchers to detect disease-related biochemical changes at significantly earlier stages and with greater specificity.³ This shift reflects a broader recognition that human health is shaped by dynamic interactions between genetic predisposition, environmental exposures, behavioral patterns, and physiological rhythms.⁴

In particular, the expanding use of genomic and transcriptomic biomarkers has opened new frontiers in early-life and developmental diagnostics.⁵ The emergence of non-invasive prenatal genomic testing, particularly through the analysis of cell-free fetal DNA and RNA in maternal plasma, exemplifies how biochemical signals originating from the fetus can now be monitored safely and accurately during pregnancy.⁶ At the same time, developmental disorders, once understood primarily through anatomical or clinical features, are increasingly being reevaluated through their molecular pathways, offering improved clarity on the biochemical and genetic determinants of congenital conditions.^{6,7}

Beyond genomics, recent breakthroughs in salivary proteomics, secretome prediction, and metabolic pathway analysis have propelled non-invasive biomarkers into mainstream clinical and public health applications.⁸ Saliva, breath, and environmental samples now serve as valuable matrices for assessing metabolic capacity, toxicant exposure, addiction biology, and inflammatory states.⁹ The rise of computational approaches, particularly bioinformatics pipelines integrating secretome prediction, protein-protein network analysis, and microRNA regulatory mapping, has greatly accelerated biomarker discovery, enabling rapid *in silico* screening before experimental validation. These innovations represent a crucial step toward accessible, population-level diagnostics.^{10,11}

Simultaneously, environmental and behavioral determinants of biochemical traits have gained recognition as essential components of diagnostic interpretation. Microplastic contamination, endocrine-disrupting chemicals, dietary patterns, cultural traditions, and lifestyle behaviors all influence biochemical markers in ways that cannot be fully explained by genetics alone.¹²⁻¹⁴ This broader biocultural and environmental context is vital for interpreting metabolic variation across individuals and populations, especially in an era where globalized lifestyles intersect with local traditions and environmental pressures.^{15,16}

Another layer of complexity arises from circadian physiology. Biochemical processes, including hormone secretion, enzymatic activity, and metabolic regulation, exhibit intrinsic 24-hour oscillations driven by central and peripheral clocks. Disruptions to these rhythms can alter disease

risks and biomarker profiles, underscoring the importance of temporal biology in diagnostics.^{17,18} Recent applications of artificial intelligence have enabled prediction and modeling of these rhythmic biochemical patterns, offering a promising foundation for circadian-aware diagnostic strategies and chronotherapeutic optimization.¹⁹

Taken together, these developments point toward a new era of integrative biochemical diagnostics, one that unites prenatal genomics, molecular biomarker discovery, environmental biosensing, cultural and behavioral determinants, and temporal physiological modeling.^{1,4-5} This short review synthesizes these interconnected domains to highlight how modern biochemical diagnostics increasingly reflect the complex, multi-layered nature of human health. By bridging insights from molecular sciences, bioinformatics, environmental health, chronobiology, and population biology, integrative diagnostics promise a more comprehensive and personalized approach to disease prevention, early detection, and precision medicine.^{2,4}

2. PRENATAL AND DEVELOPMENTAL GENOMIC BIOMARKERS

2.1. Cell-Free Fetal DNA and RNA in Maternal Circulation

The discovery of cell-free fetal DNA (cffDNA) and cell-free fetal RNA (cffRNA) in maternal plasma has revolutionized prenatal diagnostics by introducing a safe, non-invasive approach to assess fetal genetic conditions. These nucleic acids originate primarily from placental trophoblasts undergoing apoptosis and are released into maternal circulation from the earliest stages of pregnancy. Their biochemical properties, short fragment length, specific methylation signatures, and rapidly changing concentrations, allow them to serve as sensitive markers of fetal status. Unlike traditional invasive procedures such as amniocentesis or chorionic villus sampling, the analysis of cfDNA and cfRNA poses no procedural risk to the fetus, making it ideal for early genomic screening.^{6,20}

The unique molecular characteristics of fetal-derived nucleic acids enable highly accurate applications in Non-Invasive Prenatal Testing (NIPT). Differences in fragment size between fetal and maternal DNA, as well as distinct epigenetic patterns, allow for computational enrichment and targeted sequencing of the fetal component. Similarly, fetal cfRNA provides a dynamic window into placental and developmental gene expression, offering additional insights into physiological processes, placental health, and emerging pregnancy complications. Together, cfDNA and cfRNA form the biochemical backbone of modern prenatal genomics.^{6,20}

To illustrate the biological and analytical distinctions between maternal and fetal cell-free nucleic acids, Table 1 summarizes key biochemical features relevant to diagnostic interpretation.^{6,20}

Table 1. Biochemical Characteristics of Maternal and Fetal Cell-Free Nucleic Acids^{6,20}

Characteristic	Maternal cfDNA / cfRNA	Fetal cfDNA / cfRNA
Primary origin	Multiple maternal somatic tissues	Placental syncytiotrophoblasts
Typical fragment size	~166 bp	~143–145 bp (shorter fragments)
Methylation pattern	Tissue-specific, generally more methylated	Distinct hypomethylated regions enabling discrimination
RNA dynamics	More stable expression patterns	Developmentally regulated, reflecting placental and fetal physiology
Release mechanism	Apoptosis, necrosis, and extracellular vesicles	Predominantly trophoblast apoptosis
Clearance half-life	~15–30 minutes	~15–30 minutes (rapid turnover)
Diagnostic applications	Background DNA; may obscure fetal signals	Aneuploidy screening, fetal sex determination, monogenic disease applications

The distinctions highlighted in Table 1 underscore why cfDNA and cfRNA have become powerful tools in prenatal diagnostics. The shorter fragment length and characteristic hypomethylation of fetal nucleic acids provide natural biochemical markers that allow computational pipelines to enrich fetal sequences despite their relatively low abundance in maternal blood. Similarly, the dynamic transcriptomic patterns of cfRNA offer real-time reflections of placental function and fetal development, expanding the diagnostic reach beyond chromosomal abnormalities to include conditions such as preeclampsia, fetal growth restriction, and placental dysfunction. These biochemical signatures not only enhance the accuracy and robustness of NIPT but also serve as foundational elements for future multi-omic approaches aimed at refining risk prediction and maternal–fetal health monitoring.^{6,20}

2.2. Developmental Pathways as Diagnostic Targets

The molecular basis of congenital disorders is increasingly understood through the lens of disrupted developmental pathways. During fetal organogenesis, tightly controlled biochemical signaling networks, including Notch, Wnt, Hedgehog, BMP, and VEGF-related angiogenic pathways, coordinate cellular proliferation, differentiation, and tissue patterning. Disturbances in these pathways, whether due to genetic mutations, vascular insufficiency, inflammatory insults, or environmental exposures, can lead to structural malformations that manifest clinically at birth. This perspective shifts congenital disease diagnostics from purely anatomical descriptions toward mechanistic interpretations rooted in molecular biochemistry.^{21,22}

Neonatal intestinal atresia exemplifies this paradigm. Once attributed mainly to mechanical or vascular events, it is now recognized to involve complex interactions between genetic regulators of intestinal morphogenesis and biochemical responses to ischemic injury. For example, aberrant Notch signaling can impair epithelial differentiation, Wnt pathway dysregulation can alter crypt–villus architecture, Hedgehog signaling contributes to mesenchymal–epithelial communication, and inflammatory cytokines such as TNF- α and IL-6 may induce apoptosis or interfere with angiogenesis during critical windows of fetal development. Together, these networks form an integrated biochemical landscape that determines intestinal continuity and structure.^{21,22}

To synthesize the principal molecular pathways relevant to developmental diagnostics, Table 2 summarizes key biochemical signaling systems, their physiological roles, and examples of congenital disorders associated with their disruption.^{21,22}

Table 2. Major Developmental Signaling Pathways and Their Diagnostic Relevance^{21,22}

Signaling Pathway	Primary Biological Role	Examples of Disruption in Congenital Conditions
Notch Pathway	Regulates cell fate decisions, epithelial differentiation	Intestinal atresia, cardiac septation defects
Wnt/ β -catenin Pathway	Controls proliferation, stem cell maintenance, tissue patterning	Limb malformations, gastrointestinal tract anomalies
Hedgehog (Shh) Pathway	Governs mesenchymal–epithelial signaling, organ segmentation	Foregut malformations, vertebral defects
BMP/TGF- β Pathways	Modulate growth, apoptosis, and tissue remodeling	Skeletal abnormalities, gastrointestinal atresias
VEGF/Angiogenic Pathways	Support vascular formation and tissue oxygenation	Vascular disruption anomalies, ischemic-related atresias
Inflammatory Cytokine Pathways (TNF- α , IL-6)	Influence apoptosis, angiogenesis, and immune responses	Intrauterine inflammation–related defects, impaired gut morphogenesis

As shown in Table 2, each biochemical pathway contributes to a specific dimension of embryonic development, and perturbations can produce predictable structural or functional outcomes. Notch and Wnt signaling regulate epithelial continuity and stem cell activity within the developing intestine, making them particularly relevant to disorders such as intestinal atresia. Hedgehog pathways coordinate cross-talk between mesenchymal and epithelial layers, while angiogenic pathways determine whether developing tissues receive adequate vascular support. Inflammatory cytokines further interact with these systems by modulating apoptosis and vascular remodeling, especially under maternal stressors or infection. Recognizing these pathways in clinical diagnostics enables earlier detection, refines differential diagnoses, and supports the development of targeted molecular therapies that may one day complement or reduce the need for surgical interventions in congenital disorders.^{21,22}

3. BIOINFORMATICS-DRIVEN SALIVARY AND METABOLIC BIOMARKERS

3.1. In Silico Discovery of Metabolic Biomarkers

Advances in bioinformatics have transformed the discovery of metabolic biomarkers by enabling researchers to identify, prioritize, and characterize candidate molecules long before laboratory or clinical validation. Conventional biomarker discovery often relied on empirical screening or high-cost wet-lab assays, which limited scalability and accessibility. In contrast, modern computational pipelines integrate public databases, machine learning algorithms, and systems biology approaches to rapidly reveal molecular patterns linked to disease states, drug metabolism, or environmental exposures. These in silico frameworks are particularly powerful when applied to accessible biofluids such as saliva, which contains proteins, peptides, metabolites, and nucleic acids that mirror systemic physiological processes.^{10,23}

Nicotine metabolism represents a prominent example of how bioinformatics can elucidate metabolic pathways and reveal novel diagnostic candidates. Through curated databases such as KEGG, CTD, GeneCards, and salivary proteome repositories, genes involved in nicotine biotransformation can be systematically mapped, revealing key contributors such as CYP2A6, FMO3, GSTP1, and UGT2B10. Computational tools further refine these candidates by assessing secretion potential, transcriptomic expression in salivary glands, protein–protein interaction networks, and regulatory microRNA binding sites. This multilayered approach allows researchers to predict which metabolic enzymes are not only biologically relevant but also biochemically detectable in saliva, turning a traditionally underutilized biofluid into a viable matrix for metabolic phenotyping.^{10,23}

The advantages of in silico biomarker discovery extend beyond speed and cost-efficiency. Because computational methods rely on integrative datasets, they can capture the complex interplay between genetic variation, biochemical function, and molecular regulation. This is especially valuable in metabolic processes influenced by environmental factors, behavioral patterns, or cultural determinants, where direct tissue sampling is impractical or impossible. Bioinformatics thus broadens the scope of biomarker discovery from isolated candidate molecules to entire biochemical networks, offering a more holistic understanding of metabolic variability. As computational tools continue to advance, incorporating machine learning–based predictions, multi-omic integration, and cloud-scale datasets, the potential for non-invasive, saliva-based metabolic diagnostics will expand further, bridging personalized medicine with scalable public health applications.^{10,23}

3.2. MicroRNAs and Protein Networks as Diagnostic Layers

While individual metabolic enzymes provide valuable information about physiological processes, a deeper understanding of disease mechanisms emerges when these proteins are viewed within the broader context of regulatory networks. MicroRNAs (miRNAs) and protein–protein interaction (PPI) networks offer two powerful layers of biological regulation that refine biomarker discovery and enhance diagnostic precision. miRNAs act as post-transcriptional regulators that can suppress or modulate gene expression, often affecting entire metabolic pathways rather than single genes. Similarly, PPI networks reveal how enzymes, transporters, and structural proteins interact to maintain biochemical homeostasis or, conversely, propagate dysfunction when disrupted. Mapping these interconnected systems through bioinformatics strengthens the predictive accuracy of candidate biomarkers and highlights those most likely to exert systemic influence.^{10,23–24}

In the context of nicotine metabolism, for example, bioinformatics analyses have shown that GSTP1 and UGT2B10 occupy central positions within salivary protein networks, suggesting a higher likelihood of detectability and clinical relevance. These proteins are not isolated actors; they are embedded in detoxification and xenobiotic metabolism networks regulated by miRNAs such as hsa-miR-155 and hsa-miR-27b. The integration of miRNA prediction platforms (e.g., TargetScan, miRTarBase) with network analysis tools (e.g., STRING, Cytoscape) enables the construction of multilayered biomarker profiles that reflect not only biochemical activity but also transcriptional and post-transcriptional regulation. Such insights are particularly valuable for non-invasive diagnostics, where the stability of biomarkers, their secretion patterns, and their regulatory context determine their detectability in saliva or other biofluids.^{10,23-24}

To summarize key examples of regulatory elements relevant to salivary metabolic biomarkers, Table 3 lists representative proteins, their biological roles, and associated regulatory miRNAs identified through computational analysis.^{10,23-24}

Table 3. Representative Protein Biomarkers and miRNA Regulators Relevant to Salivary Metabolic Diagnostics^{10,23-24}

Protein Biomarker	Biological Function	Associated Regulatory miRNAs	Diagnostic Relevance
GSTP1	Detoxification of xenobiotics; antioxidant defense	hsa-miR-155, hsa-miR-133a	Central detoxification enzyme with strong salivary detectability
FMO3	Phase I nicotine and xenobiotic metabolism	hsa-miR-27b, hsa-miR-124	Involved in nicotine oxidation; associated with metabolic variability
UGT2B10	Glucuronidation of nicotine metabolites	hsa-miR-27a/b	Key enzyme in nicotine clearance; robust candidate for saliva-based monitoring
CYP2A6 (regulatory reference)	Primary liver enzyme for nicotine metabolism	hsa-miR-126, hsa-miR-155	Not secreted, but regulates upstream metabolic flux

The relationships illustrated in Table 3 highlight the value of examining metabolic biomarkers within a systems framework. Proteins like GSTP1 and UGT2B10 appear not only as individual markers but as central nodes within detoxification networks, which enhances their diagnostic reliability. The involvement of regulatory miRNAs adds another dimension, helping explain interindividual metabolic variability and enabling the development of composite biomarker panels that combine protein-level and regulatory-level insights. As bioinformatics tools become increasingly sophisticated, these multi-layered biomarker models will likely guide the next generation of non-invasive diagnostics, offering higher accuracy, mechanistic clarity, and predictive value across a range of metabolic and environmental health applications.^{10,23-24}

4. ENVIRONMENTAL AND LIFESTYLE BIOMARKERS

4.1. Microplastic Exposure as a Biochemical Risk Indicator

Environmental exposures increasingly shape the biochemical landscape of human health, with microplastics emerging as one of the most pervasive and understudied contaminants. Microplastics, defined as plastic particles less than 5 mm in diameter, originate from the degradation of larger plastic waste or from industrially manufactured microbeads found in consumer products. These particles have been detected across all environmental compartments, including air, food, soil, and drinking water. Their small size, hydrophobic surface, and chemical composition enable them to act as carriers for toxic additives such as phthalates, bisphenol A (BPA), and persistent organic pollutants, creating complex exposure profiles that may disrupt endocrine, immune, and metabolic systems.^{13,25}

From a biochemical standpoint, microplastics represent both physical and chemical stressors. Physically, they may induce gastrointestinal inflammation, oxidative stress, or microbiome dysbiosis upon ingestion. Chemically, the plastic-associated additives they carry can interfere with hormonal signaling, mitochondrial function, and xenobiotic metabolism. While research on their long-term health implications remains in early stages, emerging evidence suggests potential links to metabolic syndrome, reproductive dysfunction, and immune dysregulation. These concerns highlight the growing need for accessible detection tools that democratize environmental monitoring and empower communities to assess their own exposure risk.^{13,25}

Traditional microplastic detection techniques, such as FTIR spectroscopy, Raman microscopy, and scanning electron microscopy, offer high analytical precision but are costly, labor-intensive, and limited to specialized laboratories. To bridge this gap, simplified, low-cost detection methods have been developed to enable rapid and visible assessment outside laboratory settings. One such innovation combines manual filtration, selective staining with Nile Red, and UV-based fluorescence visualization, providing a practical alternative for households, schools, and community health initiatives. This approach allows users to identify microplastic contamination in tap water within minutes, transforming environmental health surveillance into an accessible biochemical diagnostic activity.^{13,25}

The emergence of these accessible detection tools signals a shift toward participatory environmental diagnostics, where biochemical screening is no longer confined to academic centers but can be integrated into public health education and community engagement. As environmental exposures become increasingly recognized as key determinants of biochemical health, incorporating microplastic monitoring into broader diagnostic frameworks can provide valuable insights into both acute and chronic health risks. Ultimately, environmental biosensing technologies, especially those designed to be low-cost and user-friendly, represent an important frontier in integrative biochemical diagnostics, linking individual health monitoring with ecological stewardship.^{13,25}

4.2. Biocultural and Behavioral Determinants of Biochemistry

Human biochemical profiles are shaped not only by genetics and environment but also by the cultural and behavioral contexts in which individuals live. Culture influences dietary patterns, habitual exposures, traditional practices, and lifestyle behaviors, each of which exerts measurable biochemical effects. For example, long-standing dairy consumption in certain Northern European populations contributed to the evolutionary

selection of lactase persistence, while culturally mediated drinking patterns intersect with the high prevalence of the ALDH2*2 variant in East Asian groups, influencing alcohol metabolism and associated health outcomes. Similarly, differential use of herbal medicines, fasting traditions, or region-specific environmental exposures (such as indoor biomass smoke) can produce biochemical signatures that are culturally patterned. These biocultural determinants highlight the need for diagnostic frameworks that account for social and behavioral context rather than relying solely on genetic ancestry.^{14,26}

Recent bioinformatics-driven analyses reinforce the importance of cultural factors by demonstrating that population-level biochemical traits can be partially predicted using molecular data enriched with lifestyle metadata. Studies integrating genomic, transcriptomic, and biomarker datasets have identified culturally stratified patterns in detoxification pathways, inflammatory markers, xenobiotic metabolism, and oxidative stress responses. These findings illustrate that cultural identity, often approximated by ethnicity or geographic region, encapsulates a set of lived experiences with biological consequences. Incorporating these dimensions into diagnostic interpretation improves accuracy, prevents misattribution of traits to genetics alone, and supports more equitable approaches to precision medicine.^{14,26}

To summarize representative examples of how cultural and behavioral factors shape biochemical traits, Table 4 highlights culturally influenced biomarkers, their underlying pathways, and the lifestyle or cultural behaviors associated with their variation.^{14,26}

Table 4. Selected Biochemical Traits Influenced by Cultural and Behavioral Practices^{14,26}

Biochemical Trait / Marker	Underlying Pathway	Associated Cultural or Behavioral Factor	Diagnostic Implications
Lactase activity (LCT expression)	Carbohydrate digestion	Long-standing dairy consumption in Northern Europeans	Guides dietary assessment and lactose intolerance diagnosis
ALDH2-mediated acetaldehyde metabolism	Alcohol detoxification	Alcohol consumption traditions in East Asian populations	Predicts flushing response, cancer risk, and alcohol sensitivity
CYP2D6 / CYP3A4 variability	Drug metabolism and xenobiotic clearance	Dietary habits, herbal medicine use, regional pharmacologic exposures	Influences individualized drug dosing and pharmacogenomic decisions
Inflammatory cytokine levels (IL-6, TNF-α)	Immune activation and metabolic regulation	Diet quality, stress patterns, traditional fasting practices	Useful for interpreting metabolic and inflammatory disorders
Oxidative stress markers	Antioxidant defense and mitochondrial activity	Environmental exposures (e.g., biomass smoke, urban pollution)	Supports environmental health risk assessment

The examples in Table 4 demonstrate how cultural practices, lifestyle behaviors, and local environmental conditions intersect to shape biochemical traits in meaningful ways. Ignoring these influences may lead to diagnostic inaccuracies, such as misclassifying culturally mediated metabolic traits as purely genetic or failing to recognize environmental drivers of inflammation or oxidative stress. By recognizing the biocultural dimension of human biochemistry, clinicians and researchers can better contextualize biomarker interpretation, improve risk prediction models, and tailor interventions to the lived realities of diverse populations. This integrative approach strengthens the precision and fairness of biochemical diagnostics, bridging molecular science with sociocultural understanding.^{14,26}

5. PHYSIOLOGICAL RHYTHMS AND AI-PREDICTED BIOCHEMICAL DYNAMICS

5.1. Circadian Regulation of Biochemical Pathways

Circadian rhythms govern a substantial portion of human biochemical activity, exerting timed control over hormone secretion, metabolic flux, enzymatic activity, and cellular homeostasis. These intrinsic 24-hour oscillations are orchestrated by a central pacemaker in the suprachiasmatic nucleus (SCN), which synchronizes peripheral clocks across organs through neural, hormonal, and metabolic cues. Core clock genes, including *CLOCK*, *BMAL1*, *PER*, and *CRY*, form transcriptional–translational feedback loops that regulate rhythmic expression of downstream metabolic pathways. As a result, key biochemical markers fluctuate predictably throughout the day, generating distinct temporal signatures that influence disease susceptibility, drug metabolism, and diagnostic interpretation.^{19,27}

Hormonal rhythms provide particularly well-characterized examples of circadian control. Melatonin peaks at night and plays a central role in sleep regulation and antioxidative defense, whereas cortisol exhibits a robust morning surge essential for energy mobilization and stress readiness. Insulin sensitivity oscillates across the 24-hour cycle, with daytime peaks aligning with feeding patterns and metabolic demands. Even immune activity, thermoregulation, and gastrointestinal motility display circadian rhythmicity. Disruption of these rhythms, through shift work, travel across time zones, sleep irregularity, or chronic stress, can dysregulate metabolic health, increase inflammatory burden, and alter the baseline values of biochemical markers used in clinical diagnostics.^{19,27}

Recognizing circadian variability is essential for accurate interpretation of laboratory tests and biomarker profiles. A biochemical value considered “abnormal” at one time of day may be physiologically appropriate at another, highlighting the need for time-aware diagnostic frameworks. Moreover, many diseases, including metabolic syndrome, cardiovascular disorders, and mood disorders, arise partly from chronobiological disruption, making circadian biomarkers useful not only for diagnosis but also for risk stratification and treatment planning. This interplay between biochemical rhythms and health outcomes has given rise to the field of chronobiology-informed diagnostics, which aims to integrate temporal patterns into both clinical practice and personalized health monitoring.^{19,27}

As advances in biosensing technologies and wearable devices continue to generate continuous physiological data streams, circadian signatures can now be captured with unprecedented granularity. These developments set the stage for artificial intelligence–driven models that can predict, simulate, and interpret rhythmic biochemical processes, forming the focus of the next section. Ultimately, understanding the circadian regulation of biochemical pathways provides the temporal foundation upon which AI-enhanced diagnostics can be built.^{19,27}

5.2. Artificial Intelligence for Time-Series Biomarker Prediction

Artificial intelligence (AI) has emerged as a transformative tool for modeling circadian and ultradian fluctuations in biochemical markers, enabling the prediction of physiological states that traditionally required invasive or prolonged monitoring. Machine learning and deep learning algorithms, particularly recurrent neural networks (RNNs), long short-term memory (LSTM) models, and temporal convolutional networks, are well suited for capturing nonlinear, time-dependent patterns inherent in hormone secretion, metabolic flux, and autonomic rhythms. These computational tools allow researchers and clinicians to predict biochemical marker trajectories such as melatonin rise, cortisol awakening response, glucose excursions, or shifts in metabolic enzyme activity, providing a dynamic window into physiological regulation that surpasses static laboratory measurements.^{19,28}

AI-driven circadian modeling leverages continuous datasets obtained from wearable sensors, electronic health records, and multimodal biosignals (e.g., heart rate variability, sleep staging, body temperature). When integrated with known molecular or endocrine pathways, these datasets enable algorithms to learn individualized patterns and generate personalized predictions of biochemical timing. Such predictions can inform optimal diagnostic sampling windows, support chronotherapy planning, and detect early signs of rhythm disruption that may precede clinical symptoms. In this way, AI enhances the interpretative power of biochemical diagnostics by embedding temporal context into health assessment.^{19,28}

To illustrate applications of AI in modeling biochemical rhythms, Table 5 summarizes representative biomarker domains, the types of AI models commonly used to analyze them, and the diagnostic or clinical utilities of these predictions.^{19,28}

Table 5. Representative AI Applications for Modeling Circadian and Biochemical Rhythms^{19,28}

Biomarker or Physiological Domain	Common AI Models Used	Clinical or Diagnostic Utility
Melatonin and sleep-related markers	RNNs, LSTM models	Predict sleep timing, circadian phase, and rhythm disruptions
Cortisol diurnal cycle	Temporal CNNs, LSTM hybrids	Support stress assessment, adrenal evaluation, and optimal sampling windows
Glucose–insulin dynamics	Time-series ML models, gradient boosting, LSTM models	Improve diabetes monitoring, predict glycemic excursions, guide feeding/therapy timing
Autonomic and metabolic rhythms	Multimodal deep learning	Detect early rhythm instability linked to cardiometabolic risk
Activity-based physiological proxies (e.g., heart rate variability)	Machine learning classification, ensemble models	Infer biochemical rhythm patterns when direct biomarkers are not measured

As shown in Table 5, AI methods not only model direct biochemical measurements but also infer underlying rhythms from physiological proxies such as activity, temperature, or heart rate patterns. This capability is particularly valuable in real-world settings where continuous biochemical sampling is impractical. By linking observable signals to hidden biochemical cycles, AI expands diagnostic reach beyond traditional laboratory tests, enabling personalized chronobiological profiling at scale. As algorithms become increasingly sophisticated and datasets grow in diversity, AI-powered circadian models hold strong potential for guiding preventive health strategies, identifying early dysregulation, and optimizing interventions according to each individual’s biological timing.^{19,28}

6. INTEGRATIVE FRAMEWORK AND FUTURE DIRECTIONS

6.1. A Unified Model for Multidimensional Biochemical Diagnostics

The rapid expansion of biochemical diagnostics across genomics, metabolomics, environmental biosensing, and chronobiology calls for an integrated framework capable of connecting these traditionally separate domains. Modern health trajectories are shaped by interactions between genetic predisposition, developmental signaling pathways, metabolic regulation, environmental exposures, cultural habits, and circadian timing. As each component contributes a distinct layer of biological information, single-modality diagnostics often fail to capture the full complexity of disease processes or personalized health states. A unified model seeks to bridge these layers, offering a holistic understanding of how biochemical signals emerge, fluctuate, and manifest clinically.^{1,4}

At the foundation of this integrative model lies prenatal and developmental biology, which provides insight into the earliest determinants of health and disease. Biomarkers derived from cell-free fetal DNA and RNA reveal genetic and epigenetic landscapes long before birth, while developmental signaling pathways illuminate structural and functional outcomes shaped in utero. On this developmental backdrop unfolds the metabolic and molecular phenotype of an individual, increasingly accessible through saliva-based protein markers, metabolic enzymes, and regulatory miRNAs identified via bioinformatics pipelines. These markers not only reflect intrinsic biochemical processes but also serve as modifiable indicators influenced by behavior, pharmacologic exposures, and environmental conditions.^{6,10}

Environmental diagnostics add a crucial third dimension. Microplastic exposure, endocrine disruptors, and region-specific contaminants create external biochemical pressures that shape metabolic, inflammatory, and oxidative stress pathways. Cultural practices, dietary patterns, and habitual exposures then modulate the magnitude and biological impact of these environmental pressures, forming a biocultural landscape that must be accounted for in accurate biomarker interpretation. Finally, the entire system is governed by circadian physiology, which imposes rhythmic fluctuations on virtually all biochemical processes. AI-driven models enhance this integrative framework by predicting rhythmic patterns, linking biomarkers across time, and offering dynamic assessments instead of static snapshots.^{13,14}

When these domains are combined, they form a multidimensional diagnostic architecture that more accurately reflects real-world human biology. Such a framework supports individualized risk prediction, enhances early detection of disease, and enables precision interventions tailored not

only to molecular profiles but also to lifestyle, environment, and temporal physiology. The next section will translate this conceptual model into practical components, summarized in Table 6, to guide future research and clinical application.^{4,5}

6.2. Practical Components of an Integrated Diagnostic Approach

Operationalizing a multidimensional biochemical diagnostic model requires identifying the core components that can be feasibly implemented in research, clinical practice, and public health settings. These components extend across biological matrices, analytical frameworks, and technological platforms, each contributing unique forms of information. By articulating these practical pillars, it becomes possible to design diagnostic strategies that are both comprehensive and adaptable, capable of capturing early developmental signals, metabolic variation, environmental pressures, and circadian rhythms within a single unified approach.²⁻⁴

In this context, Table 6 outlines key categories of diagnostic inputs that together form the structural backbone of an integrative biochemical framework. These domains encompass prenatal genomic indicators, salivary or metabolic biomarkers, environmental biosensing tools, culturally mediated behavioral factors, and temporally informed physiological models enhanced by artificial intelligence. Each category offers distinct advantages, and when used in combination, they provide a richer and more accurate depiction of an individual’s health trajectory than any single diagnostic modality alone.²⁻⁴

Table 6. Core Components of an Integrated Multidimensional Biochemical Diagnostic Framework^{6,10,13-14,19}

Diagnostic Domain	Primary Information Provided	Representative Tools or Biomarkers	Clinical or Public Health Utility
Prenatal and Developmental Genomics	Early genetic and epigenetic risk signals	cfDNA, cfRNA, developmental pathway markers	Early detection of congenital or developmental anomalies
Metabolic and Salivary Biomarkers	Enzyme activity, detoxification capacity, metabolic phenotype	GSTP1, UGT2B10, FMO3, regulatory miRNAs	Non-invasive metabolic screening and exposure assessment
Environmental Biosensing	Detection of contaminants and external biochemical stressors	Microplastic detection kits, pollutant markers	Community-level exposure monitoring and environmental risk profiling
Biocultural and Behavioral Contributors	Lifestyle, diet, cultural practices influencing biochemical traits	LCT activity, ALDH2 variants, cytokine patterns	Personalized interpretation of biomarkers and culturally informed medicine
Circadian and AI-Predicted Dynamics	Temporal fluctuations in biochemical signals	AI models for melatonin, cortisol, glycemic rhythms	Time-aware diagnostics and chronotherapy optimization

Table 6 illustrates how diverse diagnostic categories can be harmonized into a coherent, multidimensional system. Prenatal genomics reveals early foundations of health, while metabolic and salivary biomarkers offer accessible windows into real-time biochemical processes. Environmental biosensing contextualizes these biomarkers within exposure landscapes, and biocultural factors introduce essential behavioral and sociocultural nuance. Finally, circadian tracking and AI-driven prediction models provide the temporal scaffolding necessary to interpret biochemical data with maximal precision. Together, these elements enable a diagnostic ecosystem that is more holistic, equitable, and adaptable to the complexities of modern health. By embracing these interconnected domains, future diagnostic strategies can more accurately capture the multifactorial nature of human physiology and disease.^{6,10,13-14,19}

7. CONCLUSION

The landscape of biochemical diagnostics is rapidly evolving toward a multidimensional, integrative model that reflects the true complexity of human health. Advances in prenatal genomics have illuminated the earliest biochemical determinants of development, providing powerful non-invasive tools such as cell-free DNA and RNA analysis that enable early detection of genetic and structural abnormalities. Bioinformatics-driven discovery of salivary and metabolic biomarkers has expanded diagnostic access through low-burden sampling, while systems-level analyses incorporating microRNAs and protein networks have deepened our understanding of metabolic regulation and interindividual variability.^{6,10}

At the same time, environmental biosensing has emerged as a critical component of diagnostic interpretation, highlighting the biochemical consequences of exposures such as microplastics and endocrine disruptors, threats that were once difficult to detect outside specialized laboratories. Cultural and behavioral influences further underscore the necessity of contextualized diagnostics, demonstrating how diet, traditions, and lifestyle shape metabolic activity in ways that cannot be reduced to genetics alone. Meanwhile, circadian physiology adds a vital temporal dimension, revealing how rhythmic oscillations in hormone secretion, metabolism, and immune function influence the interpretation of biochemical markers at different times of day. Artificial intelligence enhances these insights by modeling complex time-series patterns and enabling dynamic prediction of biochemical states.^{13,14}

Together, these diverse domains form a cohesive diagnostic architecture capable of capturing genetic, metabolic, environmental, cultural, and temporal determinants of health. Such an integrative framework not only enhances the precision and accuracy of biochemical interpretation but also encourages equitable, personalized approaches to prevention, diagnosis, and therapy. As technology continues to advance, bringing together genomics, wearables, biosensors, and AI, biochemical diagnostics will increasingly move beyond isolated tests toward comprehensive models that reflect the interconnected nature of modern human physiology. The future of diagnostics lies in these intersections, where multidisciplinary insights converge to build a more complete and nuanced understanding of health across the lifespan.^{19,28}

REFERENCES

- 1) Cao H, Oghenemaro EF, Latypova A, Abosaoda MK, Zaman GS, Devi A. Advancing clinical biochemistry: addressing gaps and driving future innovations. *Frontiers in Medicine*. 2025;12:1521126. doi:10.3389/fmed.2025.1521126.
- 2) Whitfield E, White B, Denaxas S, Barclay ME, Renzi C, Lyrtatzopoulos G, et al. A taxonomy of early diagnosis research to guide study design and funding prioritisation. *Br J Cancer*. 2023;129:1527–1534. doi:10.1038/s41416-023-02450-4.
- 3) Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. *Laboratory Investigation*. 2022;102(11):1170–1181. doi:10.1038/s41374-022-00830-7.
- 4) Wen Q, Zhang Y, Liu Z, Ji WB, Li C, Yu T, et al. Chemical elements and human health from the perspective of “One Health”. *China Geology*. 2025;8(3):607-627. doi:10.31035/cg2025004.
- 5) Restrepo JC, Dueñas D, Corredor Z, Liscano Y. Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. *Cancers*. 2023;15(13):3474. doi:10.3390/cancers15133474.
- 6) Pranandi I. Fetal-maternal cell-free DNA and RNA in plasma: biochemical insights into non-invasive prenatal testing (NIPT). *International Journal of Environmental Sciences*. 2025;11(5s):28-48. doi: 10.64252/c8ttge05.
- 7) Desai R, Reddy S, Truong M, Thankam FG. Molecular basis of autism spectrum disorders. *Molecular Biology Reports*. 2025;52(1):508. doi:10.1007/s11033-025-10604-1.
- 8) Constantin V, Luchian I, Goriuc A, Budala DG, Bida FC, Cojocaru C, et al. Salivary biomarkers identification: advances in standard and emerging technologies. *Oral*. 2025;5(2):26. doi:10.3390/oral5020026.
- 9) Jasinska W, Birenzweig Y, Sharav Y, Aframian DJ, Rettman A, Hanut A, et al. Salivary Metabolomics as a Diagnostic Tool: Distinct Metabolic Profiles Across Orofacial Pain Subtypes. *International Journal of Molecular Sciences*. 2025;26(5):2260. doi:10.3390/ijms26052260.
- 10) Pranandi I. In silico prediction of salivary biomarkers associated with nicotine metabolism. *Journal of Carcinogenesis*. 2025;24(7s):195-210.
- 11) Mikheeva EV, Aulova KS, Nevinsky GA, Timofeeva AM. In Silico Analysis of miRNA Regulatory Networks to Identify Potential Biomarkers for the Clinical Course of Viral Infections. *International Journal of Molecular Sciences*. 2025;26(20):10100. doi:10.3390/ijms262010100.
- 12) doi:10.3390/ijms262010100.
- 13) Capó X, Morató M, Alomar C, Rios-Fuster B, Valls M, Compa M, et al. A biomarker approach as responses of bioindicator commercial fish species to microplastic ingestion: assessing tissue and biochemical relationships. *Biology*. 2022;11(11):1634. doi:10.3390/biology11111634.
- 14) Pranandi I. Development of a low-cost kit for microplastic detection in household tap water: a public health perspective. *J Bio Adv Sci Research*. 2025;1(2):1-16. doi:10.63721/25JBASR0110.
- 15) Pranandi I. Bioinformatics exploration of biochemical traits associated with culturally distinct populations: between genetics and identity. *J Bio Adv Sci Research*. 2025;1(3):1-19. doi:10.63721/25JBASR0127.
- 16) Crews D. Biocultural intersections: stressors, adaptability, allostasis, frailty, and aging. *J Physiol Anthropol*. 2022;41:33. doi:10.1186/s40101-022-00307-y.
- 17) Khalil WJ, Akeblersane M, Khan AS, Moin ASM, Butler AE. Environmental pollution and the risk of developing metabolic disorders: obesity and diabetes. *Int J Mol Sci*. 2023;24(10):8870. doi:10.3390/ijms24108870.
- 18) Lee Y, Wisor JP. Multi-Modal Regulation of Circadian Physiology by Interactive Features of Biological Clocks. *Biology*. 2022;11(1):21. doi:10.3390/biology11010021.
- 19) Fagiani F, Di Marino D, Romagnoli A, Travelli C, Voltan D, Di Cesare Mannelli L, et al. Molecular regulations of circadian rhythm and implications for physiology and diseases. *Signal Transduct Target Ther*. 2022;7:41. doi:10.1038/s41392-022-00899-y.
- 20) William W, Sudiyono N, Pranandi I. Artificial Intelligence in Circadian Physiology: Predicting Biochemical and Hormonal Rhythms in Health and Disease. *J Bio Adv Sci Research*. 2025;1(3):1–14. doi:10.63721/25JBASR0126.
- 21) Jayashankar SS, Nasaruddin ML, Hassan MF, Dasrilsyah RA, Shafiee MN, Ismail NAS, et al. Non-Invasive Prenatal Testing (NIPT): Reliability, Challenges, and Future Directions. *Diagnostics*. 2023;13(15):2570. doi:10.3390/diagnostics13152570.
- 22) Pranandi I. Biochemical pathways in neonatal intestinal atresia: vascular and genetic perspectives. *J Neonatal Surg*. 2025;14(7s):713-719.
- 23) Basak A, Sil A, Sarkar M. Intestinal atresia: a retrospective study of 36 neonates and risk factors to mortality in a tertiary care center, Tripura. *Int J Contemp Pediatr*. 2025;12(2):215-220. doi:10.18203/2349-3291.ijcp20250087.
- 24) Dai Y, Wu D, Carroll I, Zou F, Zou B. High-dimensional biomarker identification for interpretable disease prediction via machine learning models. *Bioinformatics*. 2025;41(5):btaf266. doi:10.1093/bioinformatics/btaf266.
- 25) Clarina S, Siswanto FM, Pranandi I, Handayani MDN, Dewi R, Regina R. Identification of miR-103a/PLEKHA1 pair as candidate biomarkers and therapeutic targets for skin aging by bioinformatics analysis. *Front Health Inform*. 2025;14(2):2245–2254.
- 26) Amobonye A, Bhagwat P, Raveendran S, Singh S, Pillai S. Environmental impacts of microplastics and nanoplastics: a current overview. *Front Microbiol*. 2021;12:768297. doi:10.3389/fmicb.2021.768297.
- 27) Bai S, Zhang L, Yan W, Wang H. A cross-sectional observational study of the association between biochemistry profiles and the risk of age-related macular degeneration. *Sci Rep*. 2025;15:8588. doi:10.1038/s41598-025-89121-x.
- 28) Aggarwal J, Singh N, Batra J. Genetics of circadian rhythm in disease and aging process. *Universa Medicina*. 2022;41(3):207–209. doi:10.18051/UnivMed.2022.v41.207-209.
- 29) Pranandi I, Tjhay F. Artificial intelligence and machine learning in biochemical and molecular diagnostics: a transformative review of current applications and future prospects. *Int J Comput Exp Sci Eng (IJCESN)*. 2025;11(3):4138–4147. doi:10.22399/ijcesn.2634.